Published in Nat Med on January 01, 1996
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol (2003) 2.32
A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci Transl Med (2012) 1.95
Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J (2000) 1.84
Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol (2010) 1.80
Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci U S A (2004) 1.75
Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 1.41
Intracellular and secreted Alzheimer beta-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons. Proc Natl Acad Sci U S A (1997) 1.26
Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ). J Biomed Biotechnol (2009) 1.25
The role of DYRK1A in neurodegenerative diseases. FEBS J (2010) 1.23
Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proc Natl Acad Sci U S A (1998) 1.22
Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J Alzheimers Dis (2010) 1.19
Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain. Neurobiol Aging (2006) 1.11
Mutations enhance the aggregation propensity of the Alzheimer's A beta peptide. J Mol Biol (2008) 1.06
Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J Neurol (2004) 1.01
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol (2008) 1.00
Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Curr Neuropharmacol (2013) 0.97
Lens defects and age-related fiber cell degeneration in a mouse model of increased AbetaPP gene dosage in Down syndrome. Am J Pathol (2002) 0.96
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci (2015) 0.96
Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLoS One (2012) 0.96
High resolution structural characterization of Aβ42 amyloid fibrils by magic angle spinning NMR. J Am Chem Soc (2015) 0.93
Mutant presenilin 1 increases the expression and activity of BACE1. J Biol Chem (2009) 0.91
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. Curr Alzheimer Res (2016) 0.90
Signaling effect of amyloid-beta(42) on the processing of AbetaPP. Exp Neurol (2009) 0.89
Increased amyloidogenic secretion in cerebellar granule cells undergoing apoptosis. Proc Natl Acad Sci U S A (1998) 0.88
An olfactory 'stress test' may detect preclinical Alzheimer's disease. BMC Neurol (2012) 0.87
Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics. Proteomics Clin Appl (2014) 0.86
Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer's disease. Int J Exp Pathol (2005) 0.86
Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome. J Neuropathol Exp Neurol (2011) 0.85
Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int J Exp Pathol (2005) 0.85
Antioxidants in Down syndrome. Biochim Biophys Acta (2011) 0.85
Protein aggregates and dementia: is there a common toxicity? J Neurol Neurosurg Psychiatry (2002) 0.84
Age-related neurodegeneration and memory loss in down syndrome. Curr Gerontol Geriatr Res (2012) 0.83
Advances on the understanding of the origins of synaptic pathology in AD. Curr Genomics (2007) 0.83
Neuropathology in the Down's syndrome brain. Nat Med (1996) 0.83
Steroids as γ-secretase modulators. FASEB J (2013) 0.82
Quantitative proteomics characterization of a mouse embryonic stem cell model of Down syndrome. Mol Cell Proteomics (2008) 0.82
New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome. Exp Neurobiol (2013) 0.82
Alzheimer's disease drug candidates stabilize A-β protein native structure by interacting with the hydrophobic core. Biophys J (2011) 0.82
Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome. Int J Geriatr Psychiatry (2010) 0.81
Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome. Neurobiol Aging (2015) 0.80
The struggle by Caenorhabditis elegans to maintain proteostasis during aging and disease. Biol Direct (2016) 0.80
Estrogen receptor-Beta variants are associated with increased risk of Alzheimer's disease in women with down syndrome. Dement Geriatr Cogn Disord (2011) 0.79
Amyloid-beta peptide Abetap3-42 affects early aggregation of full-length Abeta1-42. Peptides (2009) 0.79
Characterization of a brain permeant fluorescent molecule and visualization of Aβ parenchymal plaques, using real-time multiphoton imaging in transgenic mice. Org Lett (2014) 0.79
Involvement of notch signaling pathway in amyloid precursor protein induced glial differentiation. Eur J Pharmacol (2010) 0.79
The calcineurin inhibitor Sarah (Nebula) exacerbates Aβ42 phenotypes in a Drosophila model of Alzheimer's disease. Dis Model Mech (2015) 0.79
Promise and challenge: the lens model as a biomarker for early diagnosis of Alzheimer's disease. Dis Markers (2014) 0.78
Down syndrome and the complexity of genome dosage imbalance. Nat Rev Genet (2016) 0.77
Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma Aβ42 Concentrations in Down Syndrome Young Adults. Front Behav Neurosci (2015) 0.77
Dementia-linked amyloidosis is associated with brain protein deamidation as revealed by proteomic profiling of human brain tissues. Mol Brain (2016) 0.76
Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol (1999) 6.98
Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science (1996) 6.71
Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc (1998) 6.51
Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature (1990) 4.90
Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy". J Exp Med (1994) 4.41
Mitochondrial abnormalities in Alzheimer's disease. J Neurosci (2001) 4.39
Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science (2001) 4.32
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. Science (1992) 3.93
Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol (1995) 3.34
Truncated forms of the human prion protein in normal brain and in prion diseases. J Biol Chem (1995) 3.20
HLA-DQ and T-cell receptor genes in insulin-dependent diabetes mellitus. Cold Spring Harb Symp Quant Biol (1986) 3.15
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry (1990) 2.91
Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron (1995) 2.90
Paired helical filaments from Alzheimer disease patients contain cytoskeletal components. Proc Natl Acad Sci U S A (1985) 2.86
Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature (1997) 2.80
Molecular Probe Database: a database on synthetic oligonucleotides. Nucleic Acids Res (1992) 2.79
Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet (1998) 2.72
Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol (1996) 2.68
Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans. FASEB J (1999) 2.61
The neural cell adhesion molecule (NCAM) as a regulator of cell-cell interactions. Science (1988) 2.49
Genetic influence on the structural variations of the abnormal prion protein. Proc Natl Acad Sci U S A (2000) 2.46
A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci (1987) 2.43
Immunohistochemical localization of glial fibrillary acidic protein in human glial neoplasms. Cancer (1980) 2.26
A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J Immunol Methods (1998) 2.22
Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain (2001) 2.14
The neuropathology of Alzheimer's disease: a review with pathogenetic, aetiological and therapeutic considerations. Mech Ageing Dev (1985) 2.08
The widespread alteration of neurites in Alzheimer's disease may be unrelated to amyloid deposition. Ann Neurol (1989) 2.07
Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases. Proc Natl Acad Sci U S A (1988) 2.04
Effects of modifications of the RGD sequence and its context on recognition by the fibronectin receptor. J Biol Chem (1989) 2.00
Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett (2000) 1.98
A novel phenotype in familial Creutzfeldt-Jakob disease: prion protein gene E200K mutation coupled with valine at codon 129 and type 2 protease-resistant prion protein. Ann Neurol (1999) 1.98
Presenilin-1 mutations in Alzheimer's disease. Nature (2000) 1.97
A prospective, population-based study of the demographics, epidemiology, management, and outcome of out-of-hospital pediatric cardiopulmonary arrest. Ann Emerg Med (1999) 1.96
Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med (2000) 1.94
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
pH-dependent stability and conformation of the recombinant human prion protein PrP(90-231). J Biol Chem (1997) 1.85
Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Sträussler-Scheinker disease. Proc Natl Acad Sci U S A (1998) 1.85
Membrane environment alters the conformational structure of the recombinant human prion protein. J Biol Chem (1999) 1.83
Neuropsychological syndromes in presenile dementia due to cerebral atrophy. J Neurol Neurosurg Psychiatry (1986) 1.83
Progressive language disorder due to lobar atrophy. Ann Neurol (1992) 1.82
Typing prion isoforms. Nature (1997) 1.82
Prion protein expression in different species: analysis with a panel of new mAbs. Proc Natl Acad Sci U S A (1998) 1.80
Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression. AIDS Res Hum Retroviruses (1999) 1.80
Apolipoprotein E4 and Alzheimer's disease pathology in Lewy body disease and in other beta-amyloid-forming diseases. Lancet (1994) 1.78
Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Ann Neurol (1980) 1.78
Changes in the monoamine containing neurones of the human CNS in senile dementia. Br J Psychiatry (1980) 1.74
Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med (1986) 1.73
Neurofibrillary changes in human brain. An immunocytochemical study with a neurofilament antiserum. J Neuropathol Exp Neurol (1983) 1.72
Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest (1998) 1.70
Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem (1998) 1.68
Treatment of a false aneurysm of an intercostal artery using a covered intracoronary stent-graft and a radial artery puncture. Br J Radiol (2000) 1.66
Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol (2000) 1.66
Disease-specific patterns of locus coeruleus cell loss. Ann Neurol (1992) 1.64
Absence of protease-resistant prion protein in the cerebrospinal fluid of Creutzfeldt-Jakob disease. J Pathol (2001) 1.61
Generation of an apoptotic intracellular peptide by gamma-secretase cleavage of Alzheimer's amyloid beta protein precursor. J Alzheimers Dis (2000) 1.61
Molecular Probe Data Base: a database on synthetic oligonucleotides. Nucleic Acids Res (1993) 1.60
Bodian's silver method stains neurofilament polypeptides. Science (1981) 1.59
Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer. Dig Dis Sci (1999) 1.59
Tau, ubiquitin, and alpha B-crystallin immunohistochemistry define the principal causes of degenerative frontotemporal dementia. Arch Neurol (1995) 1.59
Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome. Oncogene (2010) 1.57
Resistance to several steroids in two sisters. J Clin Endocrinol Metab (1999) 1.57
Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol (2001) 1.57
Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem (1995) 1.56
Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene. Brain Pathol (1998) 1.56
Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry (1999) 1.55
Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. Biochemistry (2000) 1.52
Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology (2004) 1.49
Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol (1999) 1.49
Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol (1994) 1.47
Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol (1984) 1.47
Percutaneous pulmonary endoarterial biopsy in an experimental model of pulmonary hypertension. Chest (1998) 1.46
Re.: Purification of IgG monoclonal antibody by caprylic acid precipitation. J Immunol Methods (1983) 1.45
Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest (1997) 1.44
Identification of an epitope in the C terminus of normal prion protein whose expression is modulated by binding events in the N terminus. J Mol Biol (2000) 1.44
Familial mutations and the thermodynamic stability of the recombinant human prion protein. J Biol Chem (1998) 1.43
Neuronal and microglial involvement in beta-amyloid protein deposition in Alzheimer's disease. Am J Pathol (1990) 1.41
Alteration of the serotonergic nervous system in fatal familial insomnia. Ann Neurol (2000) 1.41
Polyploidy in the human nervous system. 1. The DNA content of neurones and glia of the cerebellum. J Neurol Sci (1973) 1.41
Phosphorylation of neurofilaments is altered in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol (1988) 1.40
Requirements for T cell activation by OKT3 monoclonal antibody: role of modulation of T3 molecules and interleukin 1. J Immunol (1985) 1.39
Cyclosporine in the treatment of generalized granuloma annulare. J Am Acad Dermatol (1994) 1.38
Glutaraldehyde-tanned mandril-grown grafts as venous substitutes. J Thorac Cardiovasc Surg (1991) 1.37
EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene (2006) 1.37
Lipoprotein pigments--their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain (1974) 1.37
Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am J Pathol (1996) 1.36
Myoclonic epilepsy with lafora bodies. Some ultrastructural, histochemical, and biochemical aspects. Arch Neurol (1971) 1.36
Alzheimer's disease: a correlative study. J Neurol Neurosurg Psychiatry (1986) 1.36
Paradoxes in longevity: sequence analysis of mtDNA haplogroup J in centenarians. Eur J Hum Genet (2001) 1.36
Postthymic development of CD28-CD8+ T cell subset: age-associated expansion and shift from memory to naive phenotype. J Immunol (1999) 1.34
A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet (1999) 1.34
Amyloid precursor protein in senile plaques of Alzheimer disease. Lancet (1988) 1.33
Aberrant metal binding by prion protein in human prion disease. J Neurochem (2001) 1.33